Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall survival (OS). Sorafenib plus doxorubicin combinati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: El Dika, Imane, Capanu, Marinela, Chou, Joanne F., Harding, James J., Ly, Michele, Hrabovsky, Anna D., Do, Richard K.G., Shia, Jinru, Millang, Brittanie, Ma, Jennifer, O’Reilly, Eileen M., Abou‐Alfa, Ghassan K.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571806/
https://ncbi.nlm.nih.gov/pubmed/32841541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3389
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados